Zynex Inc. (ZYXI): Price and Financial Metrics
ZYXI Price/Volume Stats
Current price | $12.71 | 52-week high | $14.75 |
Prev. close | $12.70 | 52-week low | $6.88 |
Day low | $12.65 | Volume | 162,300 |
Day high | $12.88 | Avg. volume | 314,676 |
50-day MA | $10.87 | Dividend yield | N/A |
200-day MA | $9.27 | Market Cap | 430.92M |
ZYXI Stock Price Chart Interactive Chart >
ZYXI POWR Grades
- ZYXI scores best on the Quality dimension, with a Quality rank ahead of 97.75% of US stocks.
- ZYXI's strongest trending metric is Value; it's been moving down over the last 26 weeks.
- ZYXI's current lowest rank is in the Momentum metric (where it is better than 24.39% of US stocks).
ZYXI Stock Summary
- ZYNEX INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 82.99% of US listed stocks.
- Of note is the ratio of ZYNEX INC's sales and general administrative expense to its total operating expenses; 87.34% of US stocks have a lower such ratio.
- With a year-over-year growth in debt of 161.43%, ZYNEX INC's debt growth rate surpasses 94.54% of about US stocks.
- Stocks that are quantitatively similar to ZYXI, based on their financial statements, market capitalization, and price volatility, are CVCO, LAKE, DNOW, HGBL, and DORM.
- ZYXI's SEC filings can be seen here. And to visit ZYNEX INC's official web site, go to www.zynex.com.
ZYXI Valuation Summary
- ZYXI's EV/EBIT ratio is 19; this is 30.14% higher than that of the median Healthcare stock.
- ZYXI's price/earnings ratio has moved up 21.6 over the prior 206 months.
Below are key valuation metrics over time for ZYXI.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ZYXI | 2023-12-29 | 2.0 | 6.3 | 23.1 | 19.0 |
ZYXI | 2023-12-28 | 2.0 | 6.3 | 23.1 | 19.0 |
ZYXI | 2023-12-27 | 2.0 | 6.2 | 22.9 | 18.8 |
ZYXI | 2023-12-26 | 2.0 | 6.2 | 22.7 | 18.7 |
ZYXI | 2023-12-22 | 1.9 | 6.2 | 22.6 | 18.6 |
ZYXI | 2023-12-21 | 1.9 | 6.1 | 22.4 | 18.5 |
ZYXI Growth Metrics
- Its 3 year revenue growth rate is now at 300.9%.
- Its 4 year net cashflow from operations growth rate is now at 359.24%.
- Its 5 year revenue growth rate is now at 288.07%.
The table below shows ZYXI's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 149.728 | 16.527 | 18.49 |
2022-06-30 | 142.994 | 12.805 | 19.724 |
2022-03-31 | 137.257 | 14.008 | 19.186 |
2021-12-31 | 130.301 | 6.949 | 17.103 |
2021-09-30 | 115.54 | -2.285 | 9.996 |
2021-06-30 | 100.78 | -6.743 | 5.222 |
ZYXI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ZYXI has a Quality Grade of A, ranking ahead of 95.17% of graded US stocks.
- ZYXI's asset turnover comes in at 1.459 -- ranking 6th of 186 Medical Equipment stocks.
- BLFS, MASI, and DXCM are the stocks whose asset turnover ratios are most correlated with ZYXI.
The table below shows ZYXI's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 1.459 | 0.778 | 0.274 |
2021-06-30 | 1.385 | 0.771 | 0.173 |
2021-03-31 | 1.459 | 0.776 | 0.254 |
2020-12-31 | 1.547 | 0.783 | 0.459 |
2020-09-30 | 1.683 | 0.788 | 0.648 |
2020-06-30 | 1.967 | 0.793 | 0.802 |
ZYXI Price Target
For more insight on analysts targets of ZYXI, see our ZYXI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $26.70 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Zynex Inc. (ZYXI) Company Bio
Zynex Inc., through its subsidiary, markets electro therapy products which help improve life of patients who have functional disabilities. The Company's products include muscle stimulation, inferential, and TENS devices. Zynex products are intended for home use for stroke rehabilitation, spinal cord injury rehabilitation, incontinence, and other applications.
Latest ZYXI News From Around the Web
Below are the latest news stories about ZYNEX INC that investors may wish to consider to help them evaluate ZYXI as an investment opportunity.
Full Video Coverage – Healthcare Trends, Financing, Future Directions in 2024 Panel at 3rd Palm Beach CorpGov ForumThe post Full Video Coverage – Healthcare Trends, Financing, Future Directions in 2024 Panel at 3rd Palm Beach CorpGov Forum appeared first on CorpGov. |
12 Best Healthcare Stocks For the Long-TermIn this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare industry is one of the biggest industries in the world. […] |
Healthcare Edge: Trends, Financing, Future Directions in 2024 Panel at 3rd Palm Beach CorpGov ForumHealthcare Edge and Exec Edge are please to provide complete video coverage of the third annual Palm Beach CorpGov Forum, which was held on Nov. 8, featuring a full day of panels and fireside chats. The event was composed of over 200 attendees including public and private corporations, private equity and VC funds, institutions, family offices, attorneys, investment bankers, other […] |
Zynex Ranked in Forbes List of "America's Most Successful Small-Cap Companies 2024"Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Company has been ranked within Forbes' list of America's Most Successful Small-Cap Companies for 2024. The 2024 Forbes list of America's Most Successful Small-Cap Companies can be found at www.forbes.com. |
Zynex Submits FDA Application for its Next Generation NMES DeviceZynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration ("FDA") for the M-Wave Neuromuscular Electrical Stimulation ("NMES") device. |
ZYXI Price Returns
1-mo | 24.36% |
3-mo | 42.17% |
6-mo | 58.48% |
1-year | -2.61% |
3-year | -21.76% |
5-year | 167.83% |
YTD | 16.71% |
2023 | -21.71% |
2022 | 53.47% |
2021 | -25.93% |
2020 | 71.03% |
2019 | 167.69% |
Continue Researching ZYXI
Here are a few links from around the web to help you further your research on Zynex Inc's stock as an investment opportunity:Zynex Inc (ZYXI) Stock Price | Nasdaq
Zynex Inc (ZYXI) Stock Quote, History and News - Yahoo Finance
Zynex Inc (ZYXI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...